Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis
Background: Janus kinase (JAK) inhibitors are promising for inflammatory bowel diseases (IBDs), but their long-term safety, including risks of nonmelanoma skin cancer (NMSC), is uncertain. Objectives: The objective of the study was to conduct a systematic review and meta-analysis to examine the risk...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wolters Kluwer Medknow Publications
2024-09-01
|
| Seri Bilgileri: | Dermatologica Sinica |
| Konular: | |
| Online Erişim: | https://journals.lww.com/10.4103/ds.DS-D-23-00241 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|